

Anti-ROR1 Antibody (Zilovertamab)

Introduction

Zilovertamab is a humanized monoclonal antibody that is primarily used to treat B-cell malignancies. It works by targeting ROR1 (receptor tyrosine kinase-like orphan receptor 1), blocking its signaling pathway, thereby inhibiting the growth and survival of tumor cells. Zilovertamab consists of an IgG1 subtype antibody structure that can specifically bind to and neutralize ROR1, thereby interfering with the proliferation and migration of tumor cells.

Product parameters

Alternative Names	UC-961, Cirmtuzumab
Target Accession	-
Target	ROR1
CAS number	2485779-13-1
Molecular Weight	146.14 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

